This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies, for a service agreement for a NextSeq 500 instrument. The contract has a ceiling value of $185,733.00 and a period of performance through September 11, 2024. It does not utilize a set-aside designation. The contract appears to be part of Illumina's broader federal contracting portfolio, which includes Indefinite Delivery Vehicles with the Department of Veterans Affairs for the procurement of Illumina's sequencing platforms, reagents, maintenance services, and bioinformatics products. Illumina has been awarded numerous prime federal contracts across agencies like the National Institutes of Health, Centers for Disease Control, and Department of Agriculture, primarily for the provision of advanced genomic sequencing technologies and services to support scientific research, healthcare, and diagnostic initiatives.